Talk:Dupilumab

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Dupilumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Confusing wording

This sentence is very confusing: "In an atopic dermatitis study, 85%(36 percent or 85 out of 671 patients) of patients improved their symptoms by at least 50% within twelve weeks (measured by eczema area and severity index), versus 35% in the placebo group.[10]"

The parenthetical phrase seems to contradict the 85% number preceding it. I could not access the german paper cited for that sentence to verify either number. Could someone correct this? — Preceding unsigned comment added by 2603:3024:1824:9800:C864:B758:B388:3B26 (talk) 21:25, 17 April 2017 (UTC)[reply]

Proposed Patent Information Section

To All,

I believe it is important to discuss the current patent applications of Dupilumab, in order to let people know what the current state of the art is for the medication.

If a link to Google Patents is too biased, what links should be used. Maybe USPTO?

Patents are primary sources not secondary source (same with USPTO). We need to use high quality secondary sources. Doc James (talk · contribs · email) 17:51, 30 October 2017 (UTC)[reply]

What would a secondary source for a patent look like? A tertiary source such as Google Patents couldn't be biased, as they are just reporting what the current status of the patent is, and that one exists.--Ahwchemistry (talk) 19:31, 30 October 2017 (UTC)[reply]

A "google patent"? This is just google repeating / displaying a primary source. Patents applications are not very interesting IMO. Doc James (talk · contribs · email) 20:21, 30 October 2017 (UTC)[reply]

I think patent information would be helpful to the people researching the drug, it could make clear the development whitespace that some companies are trying to fill. Google Patents is not just re-displaying the patent, it is providing useful information about the patent and its status. Ahwchemistry (talk) 23:24, 30 October 2017 (UTC)[reply]

Content like this "Regeneron currently is applying for a patent for the treatment of atopical dermatitis and other skin infections with Dupilumab.^[1]"

IMO is not notable for a generally encyclopedia on a page pertaining to the medication in question.Doc James (talk · contribs · email) 01:48, 31 October 2017 (UTC)[reply]

References

^ "Methods for treating skin infection by administering an IL-4R antagonist". Neil Graham, Marius ARDELEANU, Allen Radin, Jennifer D. Hamilton, Ariel Teper, Sanofi SA. 2015-02-26. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: others (link)

[1] "Methods for treating skin infection by administering an IL-4R antagonist". Neil Graham, Marius ARDELEANU, Allen Radin, Jennifer D. Hamilton, Ariel Teper, Sanofi SA. 2015-02-26. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: others (link)

[1]